Racial Differences in CYP3A4 Genotype and Survival Among Men Treated on Radiation Therapy Oncology Group (RTOG) 9202: A Phase III Randomized Trial

Mack Roach, Michelle De Silvio, Timothy Rebbick, David Grignon, Marvin Rotman, Harvey Wolkov, Barbara Fisher, Gerald Hanks, William U. Shipley, Alan Pollack, Howard Sandler, Deborah Watkins-Bruner

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Purpose: Inherited genotypes may explain the inferior outcomes of African American (AA) men with prostate cancer. To understand how variation in CYP3A4 correlated with outcomes, a retrospective examination of the CYP3A4*1B genotype was performed on men treated with Radiation Therapy Oncology Group (RTOG) 92-02. Methods and Materials: From 1,514 cases, we evaluated 56 (28.4%) of 197 AA and 54 (4.3%) of 1,274 European American (EA) patients. All patients received goserelin and flutamide for 2 months before and during RT (STAD-RT) ± 24 months of goserelin (long-term androgen deprivation plus radiation [LTAD-RT]). Events studied included overall survival and biochemical progression using American Society for Therapeutic Radiology and Oncology consensus guidelines. Results: There were no differences in outcome in patients in with or without CYP3A4 data. There was an association between race and CYP3A4 polymorphisms with 75% of EAs having the Wild Type compared to only 25% of AA men (p <0.0001). There was no association between CYP3A4 classification or race and survival or progression. Conclusions: The samples analyzed support previously reported observations about the distribution of CYP3A4*1B genotype by race, but race was not associated with poorer outcome. However, patient numbers were limited, and selection bias cannot be completely ruled out.

Original languageEnglish (US)
Pages (from-to)79-87
Number of pages9
JournalInternational Journal of Radiation Oncology Biology Physics
Volume69
Issue number1
DOIs
StatePublished - Sep 1 2007
Externally publishedYes

Keywords

  • Genetic polymorphisms
  • Prostate cancer
  • Race
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Fingerprint Dive into the research topics of 'Racial Differences in CYP3A4 Genotype and Survival Among Men Treated on Radiation Therapy Oncology Group (RTOG) 9202: A Phase III Randomized Trial'. Together they form a unique fingerprint.

  • Cite this

    Roach, M., De Silvio, M., Rebbick, T., Grignon, D., Rotman, M., Wolkov, H., Fisher, B., Hanks, G., Shipley, W. U., Pollack, A., Sandler, H., & Watkins-Bruner, D. (2007). Racial Differences in CYP3A4 Genotype and Survival Among Men Treated on Radiation Therapy Oncology Group (RTOG) 9202: A Phase III Randomized Trial. International Journal of Radiation Oncology Biology Physics, 69(1), 79-87. https://doi.org/10.1016/j.ijrobp.2007.03.008